New Patient ReferralsJian Wu, B.M., Ph.D.
|
Clinical/Research InterestsDr. Wu is a faculty member in the Department of Internal Medicine, Transplant Research Program, School of Medicine, and a member of the Graduate Group of Comparative Pathology, UC Davis. His major research interests are to develop innovative therapeutic approaches for liver injury and fibrosis, including pharmacological, molecular and gene therapy, as well as cell-based therapy and organ-specific or cell type-specific targeting drug or gene delivery. He uses RNA interference (RNAi) strategies to develop clinically applicable therapeutics for the treatment of liver injury and fibrosis. His recent studies have focused on delivering antioxidative genes for the improvement of donor organ quality as well as graft function and survival. |
Title: |
Associate Adjunct Professor |
Specialty: |
Gastroenterology and Hepatology |
Center/Program Affiliation: |
Transplant Center |
Other Languages: |
Chinese |
Education: |
Nantong University Medical College Nantong, Jiangsu Provide China B.M. 1983 |
|
University of Umea Umea Sweden Ph.D. 1994 |
|
Residency: |
Southeast University Medical College Nanjing, Jiangsu Province China 1983-1986 Internal Medicine, Division of Gastroenterology and Hepatology |
Fellowships: |
Thomas Jefferson University, Jefferson Medical College Philadelphia, Pennsylvania 1995-1999 Internal Medicine, Division of Gastroenterology and Hepatology Southeast University Medical College Nanjing, Jiangsu Province China 1986-1988 Internal Medicine, Division of Gastroenterology and Hepatology |
Professional Memberships: |
American Association for the Study of Liver Diseases (AASLD) American Society of Gene Therapy (ASGT) International Society of Stem Cell Research (ISRCR) |
Select Recent Publications: |
Zhang YH, Gu JF, Zhao LL, He LF, Qian WB, Wang JH, Wang YG, Qian QJ, Qian C, Wu J, Liu XY. Complete elimination of colorectal tumor xenograft by combined MnSOD and TRAIL gene-virotherapy. Cancer Research, 66:4291-4298, 2006. Zhan S-S, Jiang XS, Wu J, Halsted C, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and it is associated with liver fibrosis in vivo. Hepatology, 43:435-443, 2006. Yen DR, Zern MA, Wu J. Molecular Therapy for Hepatic Fibrosis. In: Frank Columbus Edits: Focus on Chemotherapy Research, Nova Science Publishers, Inc., Hauppauge, NY, pp. 1-23, 2006. Yamamoto N, Wu J, Zhang YH, Catana AM, Cai HB, Strom S, Novikoff PM, Zern MA. An optimal culture condition maintains human hepatocyte phenotype after long-term culture. Hepatology Research, 35:169-177, 2006. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis - where are we? World J Gastroenterol, 12:509-515, 2006. He SQ, Zhang YH, Venugopal SK, Dicus CW, Perez RV, Ramsamooj R, Nantz MH, Zern MA, Wu J. Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. Liver Transplantation, 2006. (In Press) Wu J, Nandamuri KM. Inhibition of hepatitis viral replication by siRNA. Expert Opinion in Biological Therapy, 4(10):1649-1659, 2004. Wu J, Liu L, Yen YD, Catana CM, Michael H. Nantz, Zern MA. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology, 40:195-204, 2004. Shirahashi H, Wu J, Yamamoto N, Wege H, Wager B, Okita K, Zern MA. Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transplantation, 13:197-211, 2004. Duan Y-Y, Wu J, Zhu J-L, Liu S-L, Ozaki I, Strayer DS, Zern MA. Gene therapy for human alpha 1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterology, 127:1222-1232, 2004. |